Ross C Donehower

Professor

1977 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Ross C Donehower is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles
Paclitaxel Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Antineoplastic Agents Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Topotecan Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences
Fluorouracil Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1977 2019

Immune-related adverse events requiring hospitalization: Spectrum of toxicity, treatment, and outcomes

Balaji, A., Zhang, J., Wills, B., Marrone, K., Elmariah, H., Yarchoan, M., Zimmerman, J. W., Hajjir, K., Venkatraman, D., Armstrong, D. K., Laheru, D., Mehra, R., Ho, W. J., Reuss, J. E., Heng, J., Vellanki, P., Donehower, R. C., Holdhoff, M. & Naidoo, J., Jan 1 2019, In : Journal of oncology practice. 15, 9, p. E825-E834

Research output: Contribution to journalArticle

Hospitalization
Gastroenterology
Immunotherapy
Inpatients
Referral and Consultation

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors

Beatty, G. L., Shahda, S., Beck, T., Uppal, N., Cohen, S. J., Donehower, R. C., Gabayan, A. E., Assad, A., Switzky, J., Zhen, H. & Von Hoff, D. D., Jan 1 2018, (Accepted/In press) In : Oncologist.

Research output: Contribution to journalArticle

gemcitabine
Pancreatic Neoplasms
Neoplasms
Cachexia
Neutropenia

Single-board hematology fellowship track: A 10-year institutional experience

Naik, R. P., Marrone, K., Merrill, S., Donehower, R. C. & Brodsky, R. A., Jan 25 2018, In : Blood. 131, 4, p. 462-464 3 p.

Research output: Contribution to journalLetter

Hematology

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat; a phase 2 consortium/stand Up 2 cancer study

Azad, N., El-Khoueiry, A., Yin, J., Oberg, A. L., Flynn, P., Adkins, D., Sharma, A., Weisenberger, D. J., Brown, T., Medvari, P., Jones, P. A., Easwaran, H., Kamel, I. R., Bahary, N., Kim, G., Picus, J., Pitot, H. C., Erlichman, C., Donehower, R. C., Shen, H. & 4 others, Laird, P. W., Piekarz, R., Baylin, S. B. & Ahuja, N., 2017, In : Oncotarget. 8, 21, p. 35326-35338 13 p.

Research output: Contribution to journalArticle

Azacitidine
Epigenomics
Colorectal Neoplasms
Neoplasms
Therapeutics
Leucovorin
Body Surface Area
Colorectal Neoplasms
Colon
Costs and Cost Analysis